-
2022-501346-30-00
5
2023-09-25
Newly Diagnosed Multiple Myeloma with Suboptimal Response After Autolo
-
2022-501419-15-00
5
2023-08-23
Atrial Fibrillation
-
2023-507522-16-00
5
2023-05-22
Metastatic Esophageal or Gastric Cancer
-
2024-511330-13-00
4
2023-01-17
Idiopathic Pulmonary Fibrosis
-
2023-505772-30-00
5
2022-11-09
Melanoma
-
2023-509859-13-00
5
2022-11-09
Relapsed or Refractory Multiple Myeloma (RRMM)
-
2023-505579-53-00
5
2022-10-25
Diffuse large B-cell lymphoma (DLBCL)
-
2023-505635-13-00
5
2022-06-10
Systemic lupus erythematosus
-
2024-513231-24-00
5
2022-03-22
Retinopathy of prematurity (ROP)
-
2023-503640-14-00
5
2022-02-17
Newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphobla
-
2023-505696-74-00
5
2022-02-10
systemic lupus erythematosus
-
2024-511599-33-00
5
2021-12-22
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
2024-510735-21-00
5
2021-11-26
Atherosclerotic cardiovascular disease (ASCVD)
-
2023-506256-25-00
5
2021-10-20
Active Psoriatic Arthritis
-
2023-506926-35-00
5
2021-09-24
Atherosclerotic cardiovascular disease, chronic kidney disease and sys
-
2023-507494-18-00
5
2021-09-24
Non-small cell lung cancer with ROS proto-oncogene 1, receptor tyrosin
-
2022-500237-92-00
5
2021-04-23
Newly-diagnosed high-intermediate and high-risk diffuse large B-cell l
-
2023-507263-19-00
5
2020-12-23
Advanced Non-Small Cell Lung Cancer
-
2023-508292-37-00
5
2020-03-06
Cardiovascular Disease
-
2023-509908-15-00
10
2020-01-20
Mantle Cell Lymphoma
-
2023-506184-34-00
5
2019-08-09
Advanced Malignancies
-
2024-514274-46-00
5
2019-06-21
Solid Tumors
-
2024-513912-89-00
10
2018-12-13
Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofibrosis (MF) Wit
-
2023-506136-32-00
9
2020-10-12
Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (